About Panoptes Pharma
Panoptes Pharma is a company based in Vienna (Austria) founded in 2013 was acquired by EyeGate in December 2020. Panoptes Pharma has raised $1.62 million across 2 funding rounds from investors including Austria Wirtschaftsservice and EyeGate. Panoptes Pharma offers products and services including PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel. Panoptes Pharma operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Vienna, Austria
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.62 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Austria Wirtschaftsservice
& 1 more
-
Employee Count
Not available
-
Acquired by
EyeGate
(Dec 21, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Panoptes Pharma
Panoptes Pharma offers a comprehensive portfolio of products and services, including PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel.
Treats eye diseases like Uveitis and diabetic Retinopathy.
Provides treatment for eye conditions through topical application.
Delivers therapies for various medical issues via injection.
Offers treatments for conditions like erectile dysfunction.
Funding Insights of Panoptes Pharma
Panoptes Pharma has successfully raised a total of $1.62M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Panoptes Pharma
Panoptes Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Austria Wirtschaftsservice and EyeGate.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Banking regulatory services are provided for Austrian financial institutions.
|
Locked | Locked | Locked | |
|
Therapeutics and drug delivery systems for eye diseases are developed.
|
Locked | Locked | Locked |
Investor details for Panoptes Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Panoptes Pharma
Investment portfolio details for Panoptes Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Panoptes Pharma
Detailed financials for Panoptes Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Panoptes Pharma Comparisons
Peer comparison for Panoptes Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Panoptes Pharma
Panoptes Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Panoptes Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Panoptes Pharma
Complete news archive for Panoptes Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Panoptes Pharma
Panoptes Pharma was founded in 2013.
Panoptes Pharma is headquartered in Vienna, Austria.
Panoptes Pharma is a funded company, having raised a total of $1.62M across 2 funding rounds to date.
Panoptes Pharma was established in 2013 in Vienna, Austria, within the pharmaceutical sector. Small molecule-based treatments are developed for eye conditions with significant unmet needs, including autoimmune uveitis and inflammatory diseases. The lead candidate, PP-001, functions as a specific inhibitor of an enzyme in the de novo pyrimidine pathway and is undergoing preclinical trials for uveitis and viral conjunctivitis. Operations center on advancing these therapies through clinical development.
Panoptes Pharma's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Panoptes Pharma offers PP-001, Augentropfen, Injektionen, and Systemische Arzneimittel.
Panoptes Pharma has 2 investors. Key investors include Austria Wirtschaftsservice, and EyeGate.